Chain Substituted Cannabilactones with Selectivity for the CB2 Cannabinoid Receptor

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Neuroscience

Background:

• Previous work identified cannabilactones as a novel class of selective CB2 receptor ligands.
• These compounds feature a C3 dimethylheptyl substituent, common in synthetic cannabinoids.
• Structure-activity relationship (SAR) studies are crucial for optimizing ligand properties.

Purpose of the Study:

• To explore the impact of modifying the C3 pharmacophoric side chain in cannabilactones.
• To investigate the effects of replacing the C1'-gem-dimethyl group with a cyclopentyl ring.
• To assess the influence of chain length and terminal carbon substitution (bromo, cyano) on receptor binding and activity.

Main Methods:

• Synthesis of novel cannabilactone analogs with varied C3 side chain modifications.
• Radioligand binding assays to determine receptor affinity (Ki) and selectivity (e.g., for mouse CB2 vs. rat CB1).
• Functional assays (e.g., cyclase assay) to evaluate agonist potency (EC50) and efficacy (E) at human CB2 receptors.

Main Results:

• The analog AM4346 (6-[1-(1,9-dihydroxy-6-oxo-6H-benzo[c]chromen-3-yl) cyclopentyl] hexanenitrile) demonstrated high affinity (Ki = 4.9 nM) for mouse CB2 receptors with 131-fold selectivity over rat CB1 receptors.
• AM4346 exhibited reduced species differences in affinity between mouse and human CB2 receptors compared to earlier cannabilactones.
• AM4346 acted as a potent and efficacious human CB2 receptor agonist in cyclase assays (EC50 = 3.7 ± 1.5 nM, E = 89%).

Conclusions:

• Modification of the C3 side chain, including the introduction of a cyclopentyl ring and specific terminal groups, yields potent and selective CB2 receptor ligands.
• The developed cannabilactone analogs, particularly AM4346, represent promising leads for targeting the CB2 receptor with improved pharmacological profiles.
• SAR studies were extended to biphenyl intermediates, broadening the scope for designing cannabinoid receptor modulators.